+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 16Years +
All Genders
ID07881120

Randomized Study of Afimetoran to Evaluate Skin Disease in Adults With Active Cutaneous Lupus Erythematosus Not Responding to Antimalarial Therapy

Led by Beeline Medicines Corporation · Updated on 2026-10-29

390

Participants Needed

3

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating afimetoran, an investigational oral medicine that blocks toll-like receptors 7 and 8, to see if it can improve skin disease in adults with active cutaneous lupus erythematosus CLE, with or without systemic lupus. This study focuses on adults whose disease has not responded to or who cannot tolerate antimalarial therapy. The trial is conducted in two stages under a single protocol to assess efficacy and safety. Participants are randomly assigned to receive one of two doses of afimetoran or a matching placebo capsule once daily for 24 weeks alongside their existing lupus care during the first stage. The second stage compares the chosen afimetoran dose to placebo to confirm results. After the 24-week placebo-controlled period, all participants receive afimetoran for an additional 28 weeks, totaling 52 weeks of treatment. During the study, researchers monitor changes in skin disease activity using the CLASI-A score and the percentage of participants achieving at least a 70% improvement at Week 24. Additional assessments include patient quality of life measures, lupus disease activity, and safety monitoring for adverse events up to 52 weeks. Participants follow study requirements including contraception protocols and regular evaluations throughout the trial.

CONDITIONS

Brief Title

Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus

Research Team

S

Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here